2,389
Views
7
CrossRef citations to date
0
Altmetric
Research Paper

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

Pages 2921-2931 | Received 30 Mar 2018, Accepted 12 Jul 2018, Published online: 29 Aug 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Md Ahsan Habib, Michael Povey, Giacomo Casabona, Tina Singh & Remon Abu-Elyazeed. (2023) Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines. Human Vaccines & Immunotherapeutics 19:1.
Read now
Barbara J. Kuter, Gary S. Marshall, Jaime Fergie, Elvira Schmidt & Manjiri Pawaskar. (2021) Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII. Human Vaccines & Immunotherapeutics 17:12, pages 5372-5383.
Read now
Nicola P. Klein, Ousseny Zerbo, Kristin Goddard, Weiqi Wang, Alison E. Fohner, Amy Wiesner, Vida Shokoohi, John Coller, Karin Bok & Hayley A. Gans. (2021) Genetic associations with a fever after measles-containing vaccines. Human Vaccines & Immunotherapeutics 17:6, pages 1763-1769.
Read now

Articles from other publishers (3)

Elisabeth Krow-Lucal, Mona Marin, Leah Shepersky, Lynn Bahta, Jamie Loehr & Kathleen Dooling. (2022) Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. Morbidity and Mortality Weekly Report 71:46, pages 1465-1470.
Crossref
Mawuli Nyaku, Elizabeth Richardson, Federico Martinon-Torres & Barbara J. Kuter. (2021) Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine). Pediatric Infectious Disease Journal 40:11, pages 1046-1054.
Crossref
Hardy-Thorsten Panknin & Matthias Trautmann. (2019) Masernausbrüche in Österreich und Deutschland:. ProCare 24:6-7, pages 22-24.
Crossref